However, the objective response is variable and, among tumor characteristics, PDL1 expression, tumor microenvironment (TME)—including tumor-infiltrating lymphocytes (TILs), tumor mutational burden (TMB), microsatellite instability (MSI), and/or abnormalities of the mismatch repair (MMR) system have been proposed as potential predictive markers for personalized therapy [7,8]. Here, CD274 is linked to neoplasm.